1987PubMedRequires access

Growth hormone therapy in short stature.

J Knudtzon, Dagfinn Aarskog

Open publisher page 3 citations

Abstract

Unlimited availability of growth hormone (GH), and the demonstration of increased growth velocity (GV) during GH treatment in non-GH-deficient children have suggested new indications for GH therapy in short stature. There are two principle conditions with GH-related short stature: classical growth hormone deficiency (CGHD) and growth hormone neurosecretory dysfunction (GHND). Present knowledge about the effects of GH treatment in these and other disorders of short stature are reviewed. In non-CGHD, it is not possible to predict the short-term effect on growth during GH therapy, and even if GV increases, the effect on final adult height remains to be documented. This, together with potential side effects and the high expense of GH treatment, exhort to a restricted attitude towards routine GH treatment of short children without GH deficiency.

About this research paper

What this paper is about

Unlimited availability of growth hormone (GH), and the demonstration of increased growth velocity (GV) during GH treatment in non-GH-deficient children have suggested new indications for GH therapy in short stature. There are two principle conditions with GH-related short stature: classical growth hormone deficiency (CGHD) and growth hormone neurosecretory dysfunction (GHND). Present knowledge about the effects of GH treatment in these and other disorders of short stature are reviewed. In non-CGHD, it is not possible to predict the short-term effect on growth during GH therapy, and even if GV increases, the effect on final adult height remains to be documented. This, together with potential side effects and the high expense of GH treatment, exhort to a restricted attitude towards routine GH treatment of short children without GH deficiency.

Why it matters

OpenAlex reports 3 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Unlimited availability of growth hormone (GH), and the demonstration of increased growth velocity (GV) during GH treatment in non-GH-deficient children have suggested new indications for GH therapy in short stature. There are two principle conditions with GH-related short stature: classical growth hormone deficiency (CGHD) and growth hormone neurosecretory dysfunction (GHND). Present knowledge about the effects of GH treatment in these and other disorders of short stature are reviewed. In non-CGHD, it is not possible to predict the short-term effect on growth during GH therapy, and even if GV increases, the effect on final adult height remains to be documented. This, together with potential side effects and the high expense of GH treatment, exhort to a restricted attitude towards routine GH treatment of short children without GH deficiency.

Key concepts: Short stature, Medicine, Growth hormone, Growth velocity, Growth hormone deficiency, Endocrinology, Internal medicine, Hormone

Related papers

Back to paper searchBrowse research topicsOriginal source
Growth hormone therapy in short stature. — Research Paper | ScholarLens